Last reviewed · How we verify
Background ARVs
Background ARVs are antiretroviral drugs that suppress HIV replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, and integrase inhibition.
Background ARVs are antiretroviral drugs that suppress HIV replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, and integrase inhibition. Used for HIV-1 infection (treatment and suppression).
At a glance
| Generic name | Background ARVs |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Antiretroviral therapy (combination regimen) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Background ARVs refer to the foundational antiretroviral therapy regimens used in HIV treatment, typically consisting of combinations of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase strand transfer inhibitors (INSTIs). These drugs work synergistically to block different stages of the HIV replication cycle, preventing viral multiplication and allowing immune system recovery.
Approved indications
- HIV-1 infection (treatment and suppression)
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Lipodystrophy
- Hepatotoxicity
- Lactic acidosis
Key clinical trials
- A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (PHASE2)
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
- BRAVO: Background Regimen of Raltegravir on Virologic Outcome
- A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients (PHASE2)
- BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |